A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

NCT06284317 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

290

Enrollment

NETWORK

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Adjuvant durvalumab

Sponsor

ETOP IBCSG Partners Foundation

Collaborators

[object Object]